Stock Events

Stock Events

Sangamo Therapeutics 

$0.14
197
+$0+1.28% Friday 19:59

Statistics

Day High
0.14
Day Low
0.12
52W High
0.75
52W Low
0.1
Volume
4,169,900
Avg. Volume
-
Mkt Cap
45.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.14
-0.08
-0.02
0.04
Expected EPS
-0.0575
Actual EPS
N/A

Financials

-169.45%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
115.6MRevenue
-195.88MNet Income

Analyst Ratings

10Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SGMO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics focuses on gene editing, directly competing with Sangamo's gene therapy and genome editing technologies.
Editas Medicine
EDIT
Mkt Cap304.49M
Editas Medicine operates in the CRISPR gene editing space, making it a direct competitor to Sangamo's gene editing therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.68B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing field, competing in the same space as Sangamo.
Beam Therapeutics
BEAM
Mkt Cap3.33B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor to Sangamo's gene therapy and genome editing technologies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.39B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, competing with Sangamo's gene regulation therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.51B
Ionis Pharmaceuticals develops RNA-targeted therapies, which competes with Sangamo's gene therapy and genome editing approaches.
Voyager Therapeutics
VYGR
Mkt Cap244.71M
Voyager Therapeutics focuses on gene therapy, particularly for neurological diseases, making it a competitor in the gene therapy space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical develops gene therapies for rare genetic diseases, directly competing with Sangamo's focus on genetic conditions.

About

There is no Profile data available for GBY.SG.
Show more...
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Employees
183
Country
United States
ISIN
US8006771062

Listings

LSE
GB
0R1D.LSE
STU
DE
GBY.STU
MU
DE
GBY.MU
OTC Link
US
SGMO

0 Comments

Share your thoughts

FAQ

What is Sangamo Therapeutics stock price today?▼
The current price of SGMO is $0.14 USD — it has increased by +1.28% in the past 24 hours. Watch Sangamo Therapeutics stock price performance more closely on the chart.
What is Sangamo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sangamo Therapeutics stocks are traded under the ticker SGMO.
Is Sangamo Therapeutics stock price growing?▼
SGMO stock has risen by +12.5% compared to the previous week, the month change is a -50% fall, over the last year Sangamo Therapeutics has showed a -71.28% decrease.
What is Sangamo Therapeutics market cap?▼
Today Sangamo Therapeutics has the market capitalization of 45.43M
When is the next Sangamo Therapeutics earnings date?▼
Sangamo Therapeutics is going to release the next earnings report on August 11, 2026.
What were Sangamo Therapeutics earnings last quarter?▼
SGMO earnings for the last quarter are -0.08 USD per share, whereas the estimation was 0.01 USD resulting in a -1,700% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sangamo Therapeutics revenue for the last year?▼
Sangamo Therapeutics revenue for the last year amounts to 115.6M USD.
What is Sangamo Therapeutics net income for the last year?▼
SGMO net income for the last year is -195.88M USD.
How many employees does Sangamo Therapeutics have?▼
As of May 16, 2026, the company has 183 employees.
In which sector is Sangamo Therapeutics located?▼
Sangamo Therapeutics operates in the Health & Wellness sector.
When did Sangamo Therapeutics complete a stock split?▼
Sangamo Therapeutics has not had any recent stock splits.
Where is Sangamo Therapeutics headquartered?▼
Sangamo Therapeutics is headquartered in Richmond, United States.